The earnings call reflected a mix of positive developments and challenges. While there was growth in CGuard revenue and significant progress in clinical trials and commercial preparations, the company faced increased operating expenses and a higher net loss. The anticipated delay in FDA approval also presents a challenge. However, the potential U.S. market opportunity and strategic progress provide optimism.

Company Guidance -

Q2 2025

In the first quarter of fiscal year 2025, InspireMD reported CGuard revenue of $1.53 million, marking a 1.2% year-over-year growth with 2,611 units sold, contributing to a total of approximately 64,000 implants sold to date. The company remains optimistic for the FDA approval of CGuard Prime in Q3 2025, which could potentially generate $12 million in U.S. revenue based on current market average selling prices (ASPs). Operating expenses increased by 52.5% to $11.75 million due to U.S. sales force expansion and preparation for the CGuard Prime launch. The net loss for the quarter was $11.17 million, with cash and cash equivalents totaling $26.09 million as of March 31, 2025. InspireMD is also advancing its clinical pipeline with strong progress in the C-GUARDIANS II pivotal study, anticipating first-half 2026 approval, and is preparing for the U.S. launch with a team of approximately 20 sales and marketing professionals.

CGuard Revenue Growth

CGuard revenue reached $1.53 million, reflecting a 1.2% growth year-over-year with 2,611 stents sold.

U.S. Market Opportunity

Potential revenue of $12 million in the U.S. market for CGuard Prime based on current international sales volumes.

Clinical Pipeline Progress

Strong enrollment in C-GUARDIANS II study and first patients enrolled in Tandem Lesion Early Feasibility Study.

Commercial Launch Preparations

Onboarding of 20 sales and marketing professionals and establishment of a facility in Miami for U.S. operations.

InspireMD (NSPR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NSPR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 05, 2025	2025 (Q2)	-0.26 / -	-0.22	―	―	―
May 09, 2025	2025 (Q1)	-0.20 / -0.22	-0.21	-4.76% (-0.01)	―
Mar 12, 2025	2024 (Q4)	-0.20 / -0.19	-0.16	-18.75% (-0.03)	―
Nov 12, 2024	2024 (Q3)	-0.20 / -0.16	-0.15	-6.67% (-0.01)	―
Aug 06, 2024	2024 (Q2)	-0.19 / -0.22	-0.24	8.33% (+0.02)	―
May 14, 2024	2024 (Q1)	-0.18 / -0.21	-0.53	60.38% (+0.32)	―
Mar 06, 2024	2023 (Q4)	-0.19 / -0.16	-0.6	73.33% (+0.44)	―
Nov 06, 2023	2023 (Q3)	-0.14 / -0.15	-0.58	74.14% (+0.43)	―
Aug 08, 2023	2023 (Q2)	-0.43 / -0.24	-0.59	59.32% (+0.35)	―
May 15, 2023	2023 (Q1)	-0.68 / -0.53	-0.57	7.02% (+0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NSPR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 09, 2025	$2.60	$2.60	0.00%
Mar 12, 2025	$2.79	$2.81	+0.72%
Nov 12, 2024	$2.46	$2.38	-3.25%
Aug 06, 2024	$2.96	$2.98	+0.68%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does InspireMD Inc (NSPR) report earnings?

InspireMD Inc (NSPR) is schdueled to report earning on Aug 05, 2025, TBA (Confirmed).

What is InspireMD Inc (NSPR) earnings time?

InspireMD Inc (NSPR) earnings time is at Aug 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NSPR EPS forecast?

NSPR EPS forecast for the fiscal quarter 2025 (Q2) is -0.26.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing